Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

April 19, 2024

https://www.globenewswire.com/news-release/2024/04/19/2866076/0/en/Tiziana-Life-Sciences-Announces-Study-Results-from-Intranasal-Anti-CD3-Foralumab-in-Multiple-Sclerosis-Patients-with-PIRA-Highlighted-in-Neurology-Today.html

– Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) –
– Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.